An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

MLA

Goker-Alpan, Ozlem, et al. An Open-Label Clinical Trial of Agalsidase Alfa Enzyme Replacement Therapy in Children with Fabry Disease Who Are Naïve to Enzyme Replacement Therapy. Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..ceea3cfcc1e162c175a6c61758001378&authtype=sso&custid=ns315887.

APA

Goker-Alpan, O., Longo, N., McDonald, M., Shankar, S. P., Schiffmann, R., Chang, P., Shen, Y., & Pano, A. (2016). An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.

Chicago

Goker-Alpan, Ozlem, Nicola Longo, Marie McDonald, Suma P Shankar, Raphael Schiffmann, Peter Chang, Yinghua Shen, and Arian Pano. 2016. “An Open-Label Clinical Trial of Agalsidase Alfa Enzyme Replacement Therapy in Children with Fabry Disease Who Are Naïve to Enzyme Replacement Therapy,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..ceea3cfcc1e162c175a6c61758001378&authtype=sso&custid=ns315887.